MaxCyte Inc (MXCT) - Total Assets
Based on the latest financial reports, MaxCyte Inc (MXCT) holds total assets worth $213.48 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore cash flow to debt ratio of MaxCyte Inc to assess how comfortably operating cash covers total debt obligations.
MaxCyte Inc - Total Assets Trend (2012–2024)
This chart illustrates how MaxCyte Inc's total assets have evolved over time, based on quarterly financial data. See what is MaxCyte Inc's book value for net asset value and shareholders' equity analysis.
MaxCyte Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
MaxCyte Inc's total assets of $213.48 Million consist of 71.7% current assets and 28.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.6% |
| Accounts Receivable | $4.68 Million | 2.0% |
| Inventory | $8.91 Million | 3.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how MaxCyte Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see MaxCyte Inc market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: MaxCyte Inc's current assets represent 71.7% of total assets in 2024, a decrease from 91.7% in 2012.
- Cash Position: Cash and equivalents constituted 11.6% of total assets in 2024, down from 49.9% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is inventory at 3.7% of total assets.
MaxCyte Inc Competitors by Total Assets
Key competitors of MaxCyte Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Bio-Rad Laboratories Inc
NYSE:BIO
|
USA | $9.79 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥5.03 Billion |
|
Tellgen Corp
SHE:300642
|
China | CN¥2.01 Billion |
|
Affluent Medical SAS
PA:AFME
|
France | €59.84 Million |
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
4DMEDICAL Ltd
AU:4DX
|
Australia | AU$139.55 Million |
|
Anteris Technologies Global Corp
AU:AVR
|
Australia | AU$19.07 Million |
|
Imricor Medical Systems Inc
AU:IMR
|
Australia | AU$45.79 Million |
MaxCyte Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.74 | 9.81 | 3.90 |
| Quick Ratio | 7.27 | 9.22 | 3.52 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $108.54 Million | $155.29 Million | $33.64 Million |
MaxCyte Inc - Advanced Valuation Insights
This section examines the relationship between MaxCyte Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.47 |
| Latest Market Cap to Assets Ratio | 0.35 |
| Asset Growth Rate (YoY) | -10.7% |
| Total Assets | $239.47 Million |
| Market Capitalization | $84.42 Million USD |
Valuation Analysis
Below Book Valuation: The market values MaxCyte Inc's assets below their book value (0.35x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: MaxCyte Inc's assets decreased by 10.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for MaxCyte Inc (2012–2024)
The table below shows the annual total assets of MaxCyte Inc from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $239.47 Million | -10.74% |
| 2023-12-31 | $268.27 Million | -6.41% |
| 2022-12-31 | $286.65 Million | +0.89% |
| 2021-12-31 | $284.12 Million | +448.71% |
| 2020-12-31 | $51.78 Million | +72.68% |
| 2019-12-31 | $29.99 Million | +23.56% |
| 2018-12-31 | $24.27 Million | -22.71% |
| 2017-12-31 | $31.40 Million | +95.35% |
| 2016-12-31 | $16.07 Million | +151.09% |
| 2015-12-31 | $6.40 Million | +1.58% |
| 2014-12-31 | $6.30 Million | +151.61% |
| 2013-12-31 | $2.50 Million | -11.87% |
| 2012-12-31 | $2.84 Million | -- |
About MaxCyte Inc
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based … Read more